AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
Tozorakimab met its primary endpoint in the MIRANDA trial, demonstrating the potential of IL-33 inhibition to reduce exacerbations and improve outcomes for a broad population of COPD patients. Topline ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2026 GOLD report newly highlights disease activity ...
(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
3d
More than 140,000 Americans die from COPD each year. Survival depends on more than avoiding smoking
Chronic obstructive pulmonary disease, or COPD, caused 141,733 deaths in the United States in 2023—the latest data that has ...
Higher isoflavone consumption is associated with improved respiratory health in former smokers with COPD, highlighting diet's ...
Breathing is something most of us don’t think twice about. It’s automatic, constant, and easy, until it’s not. That’s ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results